Other
Human Metapneumovirus
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Human Metapneumovirus is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
3
clinical trials
Completed2 · 67%
Withdrawn1 · 33%
Clinical Trials
Trial Activity
Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01255410·60 enrolled
Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01109329·21 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)